Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from the first of two of its Phase 3 trials that included more than 3,100 overweight or obese adults
After stopping medication, participants regained about 0.4 kg or nearly 0.9 pounds per month and were projected to reach their original body weight within about 1.7 years
Rybelsus, the only oral GLP-1, is expected to be joined by Orforglipron by 2027-28
Nonetheless, the net effect from the meta-analysis supports the combined therapy, although it exhibits considerable heterogeneity and includes very few studies
Based at the University of Lausanne in Switzerland, Thorens had a long-standing interest in insulin resistance and diabetes from both an academic and clinical perspective
One of the first things people notice when they start GLP-1 medications is that their body suddenly feelsdifferent
